CuraTeQ Biologics Private Ltd., a wholly owned subsidiary of Aurobindo Pharma Ltd., has received Good Manufacturing Practice (GMP) approval from Brazil’s National Health Surveillance Agency (ANVISA) for its biosimilars manufacturing facility in Hyderabad.
According to a stock exchange filing, ANVISA conducted a GMP inspection of the facility from May 11 to May 15, 2026. The approval follows the successful inspection of the site’s biological active pharmaceutical ingredient (API) and sterile products.
The inspection covered four biosimilar products and assessed the mammalian and microbial drug substance manufacturing facility, prefilled syringe and vial filling facility, packaging and labelling facility, as well as quality control testing and product release laboratories.
CuraTeQ’s drug substance and drug product manufacturing facility is already certified by the European Medicines Agency (EMA) and the World Health Organization (WHO).
The company said the latest ANVISA approval reaffirms its commitment to global regulatory compliance and quality standards and strengthens its capability to supply biosimilar products to the Brazilian and broader Latin American markets.
Founded in 2016 and headquartered in Hyderabad, CuraTeQ Biologics was established as a subsidiary of Aurobindo Pharma to develop high-quality biosimilars.
